Related Experiment Video
Updated: Jan 18, 2026

Determination of Fatty Acid Oxidation and Lipogenesis in Mouse Primary Hepatocytes
Published on: August 27, 2015
Isolation, Purification, and Preparation of Taxinine-Loaded Liposomes for Improved Anti-Hepatocarcinogenic Activity
Qilong Wang1, Xiaowen Wang1, Qinyang Hua1
1Department of Pharmaceutics, School of Pharmacy, Center for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu Provincial Research Center for Medicinal Function Development of New Food Resources, Jiangsu University, Zhenjiang, Jiangsu, China.
Abstract:
Liver cancer is the fourth most deadly cancer worldwide, but existing treatment options are insufficient, thus highlighting the urgent need for new therapeutic agents. Taxanes, known for their anticancer properties, provide a promising avenue for intervention. In this study, a tetracyclic taxane compound with antitumor activity (taxinine) was extracted and isolated from Taxus chinensis (T. chinensis) seeds. It was then formulated into liposomes using lecithin, cholesterol, and D-α-tocopheryl polyethylene glycol succinate (TPGS) as excipients to enhance its solubility and antitumor efficacy. The isolation of taxinine was achieved through ultrasound-assisted ethanol extraction, followed by silica gel column chromatography, MTT activity screening, and recrystallization. Afterward, the structure of taxinine was confirmed using nuclear magnetic resonance and mass spectrometry. Taxinine liposomes were prepared via the thin film dispersion method, while the particle size, polydispersity index, zeta potential, and encapsulation efficiency of the nanoliposomes were discovered to be 186.76 ± 0.08 nm, 0.226 ± 0.012, -44.34 ± 0.77 mV, and 93.75 ± 1.29%, respectively. They also showed good stability with a release rate of 85.77% ± 2.43% in phosphate-buffered solution (PBS, pH 7.4). Toxicity tests conducted on zebrafish larvae indicated that taxinine liposomes were safe in vivo. Tissue distribution study showed that the concentration of taxinine liposomes increased to varying degrees in tissues (especially liver). In vitro experiments demonstrated that taxinine liposomes significantly enhanced the inhibitory effect of taxinine on HepG2 cell growth. Overall, the nanoliposomal formulation improved the anti-liver cancer activity of taxinine, thus suggesting its potential as a therapeutic agent.
Insights
Researchers developed taxinine liposomes from Taxus chinensis seeds to treat liver cancer. This novel nanoliposomal formulation enhances taxinine
Area of Science:
- Natural Product Chemistry
- Nanotechnology
- Oncology
Background:
- Liver cancer is a leading cause of cancer death globally.
- Current treatments for liver cancer are inadequate, necessitating novel therapeutic strategies.
- Taxanes, including taxinine from Taxus chinensis, exhibit promising anticancer properties.
Purpose of the Study:
- To isolate and characterize taxinine from Taxus chinensis seeds.
- To formulate taxinine into stable, effective liposomes for enhanced liver cancer therapy.
- To evaluate the in vitro and in vivo efficacy and safety of taxinine liposomes.
Main Methods:
- Ultrasound-assisted extraction and column chromatography for taxinine isolation.
- Nuclear magnetic resonance and mass spectrometry for structural elucidation.
- Thin film dispersion method for liposome preparation and characterization (particle size, PDI, zeta potential, encapsulation efficiency).
- In vitro cytotoxicity assays on HepG2 cells and in vivo toxicity studies on zebrafish larvae.
Main Results:
- Taxinine was successfully isolated and characterized.
- Taxinine liposomes exhibited optimal characteristics: 186.76 nm size, 0.226 PDI, -44.34 mV zeta potential, and 93.75% encapsulation efficiency.
- Liposomes demonstrated good stability, controlled release, in vivo safety in zebrafish, preferential liver accumulation, and enhanced inhibition of HepG2 cell growth.
Conclusions:
- Nanoliposomal formulation significantly improves the solubility and antitumor efficacy of taxinine.
- Taxinine liposomes represent a promising therapeutic agent for liver cancer treatment.
- Further investigation into taxinine liposomes for clinical application is warranted.

